Prognostic impact of tace combined with sorafenib or lenvatinib followed by regorafenib in recurrent hepatocellular carcinoma after liver transplantation: a retrospective study
Abstract Background Tumor recurrence after liver transplantation (LT) for hepatocellular carcinoma (HCC) remains a significant challenge. This study systematically evaluates the efficacy and safety of transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) for post-LT...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14446-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849768728320802816 |
|---|---|
| author | Zhao-dan Ye Meng-chen Song Al-Kalei AMA Li Zhuang Yan Zhang Sheng-li Ye He-miao Shi Si-yi Zhong Dan Zhu Guo-hong Cao Jing-feng Zhang |
| author_facet | Zhao-dan Ye Meng-chen Song Al-Kalei AMA Li Zhuang Yan Zhang Sheng-li Ye He-miao Shi Si-yi Zhong Dan Zhu Guo-hong Cao Jing-feng Zhang |
| author_sort | Zhao-dan Ye |
| collection | DOAJ |
| description | Abstract Background Tumor recurrence after liver transplantation (LT) for hepatocellular carcinoma (HCC) remains a significant challenge. This study systematically evaluates the efficacy and safety of transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) for post-LT tumor recurrence. Methods This retrospective study included 78 patients with recurrent intrahepatic HCC after LT. Seventy patients received TACE in combination with either sorafenib or lenvatinib, followed by regorafenib. Outcomes evaluated included time to progression (TTP), post-recurrence survival (PRS), post-transplantation survival (PTS), objective response rate (ORR), and adverse events (AEs). Results The median TTP for recurrent intrahepatic HCC with combination therapy was 6 months (95% CI: 3.685–8.315), while the median PRS and PTS were 16 months (95% CI: 13.049–18.951) and 25 months (95% CI: 20.447–29.553), respectively. The ORR for intrahepatic tumors was 71.4%. AEs, including post-embolization syndrome and myelosuppression, were manageable. Conclusion TACE combined with TKIs has good efficacy and safety in the treatment of HCC recurrence post-LT and is expected to prolong survival. |
| format | Article |
| id | doaj-art-66f8d45d40df43189509294afd7d8952 |
| institution | DOAJ |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-66f8d45d40df43189509294afd7d89522025-08-20T03:03:41ZengBMCBMC Cancer1471-24072025-07-0125111010.1186/s12885-025-14446-9Prognostic impact of tace combined with sorafenib or lenvatinib followed by regorafenib in recurrent hepatocellular carcinoma after liver transplantation: a retrospective studyZhao-dan Ye0Meng-chen Song1Al-Kalei AMA2Li Zhuang3Yan Zhang4Sheng-li Ye5He-miao Shi6Si-yi Zhong7Dan Zhu8Guo-hong Cao9Jing-feng Zhang10Department of Radiology, Shulan (Hangzhou) Hospital, Shulan International Medical College, Zhejiang Shuren UniversityDepartment of Radiology, Shulan (Hangzhou) Hospital, Shulan International Medical College, Zhejiang Shuren UniversityDepartment of Radiology, Shulan (Hangzhou) Hospital, Shulan International Medical College, Zhejiang Shuren UniversityDepartment of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital, Shulan International Medical College, Zhejiang Shuren UniversityDepartment of Radiology, Shulan (Hangzhou) Hospital, Shulan International Medical College, Zhejiang Shuren UniversityDepartment of Radiology, Shulan (Hangzhou) Hospital, Shulan International Medical College, Zhejiang Shuren UniversityDepartment of Radiology, Zhejiang HospitalDepartment of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital, Shulan International Medical College, Zhejiang Shuren UniversityDepartment of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital, Shulan International Medical College, Zhejiang Shuren UniversityDepartment of Radiology, Shulan (Hangzhou) Hospital, Shulan International Medical College, Zhejiang Shuren UniversityDepartment of Radiology, Ningbo No.2 Hospital, Haishu DistrictAbstract Background Tumor recurrence after liver transplantation (LT) for hepatocellular carcinoma (HCC) remains a significant challenge. This study systematically evaluates the efficacy and safety of transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) for post-LT tumor recurrence. Methods This retrospective study included 78 patients with recurrent intrahepatic HCC after LT. Seventy patients received TACE in combination with either sorafenib or lenvatinib, followed by regorafenib. Outcomes evaluated included time to progression (TTP), post-recurrence survival (PRS), post-transplantation survival (PTS), objective response rate (ORR), and adverse events (AEs). Results The median TTP for recurrent intrahepatic HCC with combination therapy was 6 months (95% CI: 3.685–8.315), while the median PRS and PTS were 16 months (95% CI: 13.049–18.951) and 25 months (95% CI: 20.447–29.553), respectively. The ORR for intrahepatic tumors was 71.4%. AEs, including post-embolization syndrome and myelosuppression, were manageable. Conclusion TACE combined with TKIs has good efficacy and safety in the treatment of HCC recurrence post-LT and is expected to prolong survival.https://doi.org/10.1186/s12885-025-14446-9Hepatocellular carcinomaTransarterial chemoembolizationLiver transplantationRecurrenceTyrosine kinase inhibitors |
| spellingShingle | Zhao-dan Ye Meng-chen Song Al-Kalei AMA Li Zhuang Yan Zhang Sheng-li Ye He-miao Shi Si-yi Zhong Dan Zhu Guo-hong Cao Jing-feng Zhang Prognostic impact of tace combined with sorafenib or lenvatinib followed by regorafenib in recurrent hepatocellular carcinoma after liver transplantation: a retrospective study BMC Cancer Hepatocellular carcinoma Transarterial chemoembolization Liver transplantation Recurrence Tyrosine kinase inhibitors |
| title | Prognostic impact of tace combined with sorafenib or lenvatinib followed by regorafenib in recurrent hepatocellular carcinoma after liver transplantation: a retrospective study |
| title_full | Prognostic impact of tace combined with sorafenib or lenvatinib followed by regorafenib in recurrent hepatocellular carcinoma after liver transplantation: a retrospective study |
| title_fullStr | Prognostic impact of tace combined with sorafenib or lenvatinib followed by regorafenib in recurrent hepatocellular carcinoma after liver transplantation: a retrospective study |
| title_full_unstemmed | Prognostic impact of tace combined with sorafenib or lenvatinib followed by regorafenib in recurrent hepatocellular carcinoma after liver transplantation: a retrospective study |
| title_short | Prognostic impact of tace combined with sorafenib or lenvatinib followed by regorafenib in recurrent hepatocellular carcinoma after liver transplantation: a retrospective study |
| title_sort | prognostic impact of tace combined with sorafenib or lenvatinib followed by regorafenib in recurrent hepatocellular carcinoma after liver transplantation a retrospective study |
| topic | Hepatocellular carcinoma Transarterial chemoembolization Liver transplantation Recurrence Tyrosine kinase inhibitors |
| url | https://doi.org/10.1186/s12885-025-14446-9 |
| work_keys_str_mv | AT zhaodanye prognosticimpactoftacecombinedwithsorafeniborlenvatinibfollowedbyregorafenibinrecurrenthepatocellularcarcinomaafterlivertransplantationaretrospectivestudy AT mengchensong prognosticimpactoftacecombinedwithsorafeniborlenvatinibfollowedbyregorafenibinrecurrenthepatocellularcarcinomaafterlivertransplantationaretrospectivestudy AT alkaleiama prognosticimpactoftacecombinedwithsorafeniborlenvatinibfollowedbyregorafenibinrecurrenthepatocellularcarcinomaafterlivertransplantationaretrospectivestudy AT lizhuang prognosticimpactoftacecombinedwithsorafeniborlenvatinibfollowedbyregorafenibinrecurrenthepatocellularcarcinomaafterlivertransplantationaretrospectivestudy AT yanzhang prognosticimpactoftacecombinedwithsorafeniborlenvatinibfollowedbyregorafenibinrecurrenthepatocellularcarcinomaafterlivertransplantationaretrospectivestudy AT shengliye prognosticimpactoftacecombinedwithsorafeniborlenvatinibfollowedbyregorafenibinrecurrenthepatocellularcarcinomaafterlivertransplantationaretrospectivestudy AT hemiaoshi prognosticimpactoftacecombinedwithsorafeniborlenvatinibfollowedbyregorafenibinrecurrenthepatocellularcarcinomaafterlivertransplantationaretrospectivestudy AT siyizhong prognosticimpactoftacecombinedwithsorafeniborlenvatinibfollowedbyregorafenibinrecurrenthepatocellularcarcinomaafterlivertransplantationaretrospectivestudy AT danzhu prognosticimpactoftacecombinedwithsorafeniborlenvatinibfollowedbyregorafenibinrecurrenthepatocellularcarcinomaafterlivertransplantationaretrospectivestudy AT guohongcao prognosticimpactoftacecombinedwithsorafeniborlenvatinibfollowedbyregorafenibinrecurrenthepatocellularcarcinomaafterlivertransplantationaretrospectivestudy AT jingfengzhang prognosticimpactoftacecombinedwithsorafeniborlenvatinibfollowedbyregorafenibinrecurrenthepatocellularcarcinomaafterlivertransplantationaretrospectivestudy |